Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CFD | P00746 | 10/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MPL | P40238 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30142030 | 0.89 | L3MBTL1 (0.49) | L3MBTL1CYP2C9GAAKDM4EMEN1 | |
| SCHEMBL5521725 | 0.89 | L3MBTL1 (0.49) | L3MBTL1CYP2C9GAAKDM4EMEN1 | |
| SCHEMBL31389658 | 0.83 | L3MBTL1 (0.47) | L3MBTL1CYP2C9GAAKDM4EMEN1 | |
| SCHEMBL29177412 | 0.79 | GAA (0.44) | CFDCYP2C9GAAMEN1KMT2A | |
| SCHEMBL12480284 | 0.78 | ANO1 (0.47) | L3MBTL1CFDCYP2C9GAAMAPT | |
| SCHEMBL21893894 | 0.75 | MPL (0.41) | CFDMPLGAA | |
| SCHEMBL5464387 | 0.74 | L3MBTL1 (0.50) | L3MBTL1CYP2C9GAAKDM4EMEN1 | |
| SCHEMBL29838495 | 0.74 | L3MBTL1 (0.50) | L3MBTL1CYP2C9GAAKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL28093603 | 0.73 | MPL (0.40) | CFDMPLGAAKDM4E | |
| SCHEMBL13712 | 0.73 | GAA (0.55) | GAAKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385069-B2 | Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2019-08-20 | — | — | US | disclosed |
| US-20180282348-A1 | IMIDAZO[2,1-B]THIAZOLE AND 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-10-04 | — | — | US | disclosed |
| CN-107466296-A | Imidazo [2,1 b] thiazole and 5,6 glyoxalidine as S100 inhibitor simultaneously [2,1 b] thiazole | 活跃生物技术有限公司 | 2017-12-12 | — | — | CN | disclosed |
| WO-2016042172-A1 | IMIDAZO[2,1-B]THIAZOLE AND 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282348-A1 | IMIDAZO[2,1-B]THIAZOLE AND 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE DERIVATIVES USEFUL AS S100-INHIBITORS | S100B, S100P, S100A4 | L3MBTL1 4118/4885CFD 4774/4885CYP2C9 4233/4885 |
| US-10385069-B2 | Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors | S100B, S100P, S100A4 | L3MBTL1 4118/4885CFD 4774/4885CYP2C9 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.